1. Home
  2. EDN vs ANL Comparison

EDN vs ANL Comparison

Compare EDN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)

EDN

Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)

HOLD

Current Price

$20.35

Market Cap

1.1B

Sector

Utilities

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

SELL

Current Price

$15.19

Market Cap

998.8M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
EDN
ANL
Founded
1992
2004
Country
Argentina
Singapore
Employees
N/A
N/A
Industry
Electric Utilities: Central
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
998.8M
IPO Year
2007
2022

Fundamental Metrics

Financial Performance
Metric
EDN
ANL
Price
$20.35
$15.19
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
★ $38.50
$29.50
AVG Volume (30 Days)
119.2K
★ 176.6K
Earning Date
08-11-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$21.13
$243.83
Revenue Next Year
$22.69
N/A
P/E Ratio
$16.98
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.62
$0.88
52 Week High
$36.70
$17.25

Technical Indicators

Market Signals
Indicator
EDN
ANL
Relative Strength Index (RSI) 37.62 50.81
Support Level $19.42 $14.70
Resistance Level $27.54 $16.71
Average True Range (ATR) 0.97 1.22
MACD -0.05 -0.11
Stochastic Oscillator 26.44 44.17

Price Performance

Historical Comparison
EDN
ANL

About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)

Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires, mainly for residential, commercial, industrial, and public service.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: